You are here: Industry Insights > Breast Cancer

News List

Roche's I-O drug Tecentriq picks up key first-in-class breast cancer nod! fiercepharma
March 12, 2019
In a first for the immuno-oncology field, Roche’s Tecentriq has a big new approval in breast cancer.
EU committee recommends AstraZeneca’s Lynparza for breast cancer pharmaceutical-technology
March 05, 2019
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the use of Lynparza (olaparib) as monotherapy to treat breast cancer.
High Deductibles May Threaten Breast Cancer Patients' Survival drugs
March 05, 2019
Even when women have health insurance, high deductibles may delay them from having breast cancer diagnosed and treated, researchers say.
Breast Cancer Diagnosis Delays Seen With High-Deductible Health Plans drugs
March 05, 2019
Both low- and high-income women who are switched to high-deductible health plans (HDHPs) experience delays in breast cancer diagnosis and treatment, according to a study published in the March issue of Health Affairs.
EMA panel backs approval of AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza in breast cancer firstwordpharma
March 04, 2019
AstraZeneca and partner Merck & Co. on Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of the PARP inhibitor Lynparza (olaparib) as monotherapy for the treatment of HER2-nega
EMA panel backs approval of AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza in breast cancer firstwordpharma
March 03, 2019
AstraZeneca and partner Merck & Co. on Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of the PARP inhibitor Lynparza (olaparib) as monotherapy for the treatment of HER2-nega
Experimental Drug Helps Women With Deadly Type of Breast Cancer drugs
February 21, 2019
An experimental drug has shown promise in extending the lives of women suffering from a particularly aggressive and deadly type of breast cancer, according to the results of a phase 2 trial....
NICE recommends Roche’s breast cancer drug pertuzumab pharmaceutical-technology
February 19, 2019
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Roche’s Perjeta (pertuzumab) by the National Health Service (NHS) to treat early HER2-positive breast cancer, which has spread to lymph nodes.....
Price cut unlocks NICE nod for Perjeta in post-surgery breast cancer pharmaphorum
February 15, 2019
Roche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer from recurring after surgery, at the third attempt.
Researchers find new mechanism to control spread of breast cancer pharmaceutical-technology
January 23, 2019
Researchers at the Fred Hutchinson Cancer Research Center in Seattle, the US, have discovered how cells that have broken away from breast cancer tumours evaded chemotherapy and ....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page